Stock BSLN BASILEA PHARMACEUTICA AG
Add to a list
To use this feature you must be a member
Log inSign up

Company Basilea Pharmaceutica AG

Equities

BSLN

CH0011432447

Biotechnology & Medical Research

Market Closed - Swiss Exchange
Other stock markets
 16:31:59 30/04/2024 BST 		5-day change 1st Jan Change
39.5 CHF -1.74% Intraday chart for Basilea Pharmaceutica AG -3.42% +11.90%
04-09 Basilea Pharmaceutica Receives Grant for Antibiotics Program MT
04-04 Stocks Close in Green as Swiss Inflation Unexpectedly Slows MT

Business Summary

Basilea Pharmaceutica AG Allschwil, formerly known as Basilea Pharmaceutica AG, is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. It launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.

Number of employees: 147

Sales per Business

CHF in Million2022Weight2023Weight Delta
Innovative Pharmaceutical Products
100.0 %
148 100.0 % 158 100.0 % +6.68%

Sales per region

CHF in Million2022Weight2023Weight Delta
Ireland
43.6 %
41 27.9 % 69 43.6 % +66.34%
Japan
37.8 %
64 43.3 % 60 37.8 % -6.87%
Uruguay
6.5 %
7 5.0 % 10 6.5 % +37.84%
United States
3.9 %
10 6.6 % 6 3.9 % -37.76%
Sweden
2.5 %
3 2.2 % 4 2.5 % +21.87%
Canada
2.3 %
3 1.9 % 4 2.3 % +28.57%
China
1.5 %
-- 2 1.5 % -
Jordan
1.1 %
3 1.8 % 2 1.1 % -33.33%
Switzerland
0.9 %
2 1.6 % 1 0.9 % -41.67%

Managers

Managers TitleAgeSince
David Veitch CEO
 Chief Executive Officer 59 31/08/14
Adesh Kaul DFI
 Director of Finance/CFO 50 31/12/08
Gerrit Hauck CTO
 Chief Tech/Sci/R&D Officer 60 30/04/18
Marc Engelhardt CTO
 Chief Tech/Sci/R&D Officer 60 31/12/09
Laurenz Kellenberger CTO
 Chief Tech/Sci/R&D Officer 57 31/12/99
Peer Nils Schröder IRC
 Investor Relations Contact - -
Damian Heller LAW
 General Counsel 58 31/12/14
Ursula Eberhardt HRO
 Human Resources Officer 62 31/12/05

Members of the board

Members of the board TitleAgeSince
Nicole Onetto BRD
 Director/Board Member 71 26/04/17
Leonard Kruimer BRD
 Director/Board Member 66 31/12/21
Alf Gunnar Martin Nicklasson BRD
 Director/Board Member 69 08/04/13
Domenico Scala CHM
 Chairman 59 28/11/11
Carole A. Sable BRD
 Director/Board Member 62 26/04/23
Thomas Werner BRD
 Director/Board Member 68 28/11/11

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 13,079,793 11,974,303 ( 91.55 %) 1,098,157 ( 8.396 %) 91.55 %

Shareholders

NameEquities%Valuation
BASILEA PHARMACEUTICA AG
8.332 %
1,091,643 8.332 % 46 M CHF
Black Creek Investment Management, Inc.
5.066 %
663,670 5.066 % 28 M CHF
CI Investments, Inc.
4.901 %
642,065 4.901 % 27 M CHF
Braginsky Family Office AG
2.990 %
391,677 2.990 % 16 M CHF
ACATIS Investment Kapitalverwaltungsgesellschaft mbH
2.539 %
332,689 2.539 % 14 M CHF
Argenta Spaarbank NV
0.7119 %
93,267 0.7119 % 4 M CHF
Bank J. Safra Sarasin AG (Investment Management)
0.6521 %
85,439 0.6521 % 4 M CHF
Saint Olive Gestion SNC
0.5152 %
67,500 0.5152 % 3 M CHF
Apo Asset Management GmbH
0.2405 %
31,511 0.2405 % 1 M CHF
Helaba Invest Kapitalanlagegesellschaft mbH
0.1815 %
23,773 0.1815 % 993 731 CHF

Holdings

NameEquities%Valuation
BASILEA PHARMACEUTICA AG
8.33%
 1,091,643 8.33% 45,631,573 $

Company contact information

Basilea Pharmaceutica AG

Hegenheimermattweg 167b

4123, Allschwil

+41 61 606 11 11

http://www.basilea.com
address Basilea Pharmaceutica AG(BSLN)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per region

Ratings for Basilea Pharmaceutica AG

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
39.5 CHF
Average target price
70.58 CHF
Spread / Average Target
+78.69%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
BASILEA PHARMACEUTICA AG Stock Basilea Pharmaceutica AG
+11.90% 517M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.67% 42.19B
LONZA GROUP AG Stock Lonza Group AG
+44.30% 40.15B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.55% 24.63B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.66% 18.2B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.96% 12.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.57% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+16.03% 10.4B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-4.80% 9.94B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. BSLN Stock
  4. Company Basilea Pharmaceutica AG